Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Boehringer discontinues brigimadlin while others continue to struggle.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The group could soon provide clarity on CTX112’s regulatory path.
The THIO-104 study listing is live, along with questions about funding the trial.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
